Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 52 results found. Search for [ by-Joe-C.-Mathew ]

Results 1 to 21 of 52
By Joe C. Mathew
July 22, 2017
The government has set yet another deadline but lack of PoS devices and related issues are putting the fertiliser DBT programme on the back foot.


By Joe C. Mathew
Delhi, June 24, 2017
Why India cannot afford to be complacent about trade imbalances.


By Joe C. Mathew
Delhi, June 24, 2017
Farm loan waivers can bring only temporary relief. India needs long-term supply chain and technology reforms if it has to have any chance of tackling farmer discontent.


By Joe C. Mathew
NA, April 15, 2017
Proposed amendments to the RTI Act will end up serving officialdom at the cost of citizens.


By Joe C. Mathew
Delhi, March 20, 2017
In spite of favourable court verdicts, top pharmaceutical companies are losing enthusiasm for fixed dose combination medicines.


By Joe C. Mathew
Delhi, March 20, 2017
Is RBI right in stonewalling the RTI query on note ban?


By Joe C. Mathew
Delhi, February 18, 2017
The government's direct benefit transfer scheme is riddled with problems.


By Joe C. Mathew
Delhi, February 4, 2017
New US administration's move on H-1B visas and protectionist rhetoric are bad news for India's exports, especially from the information technology sector.


by Joe C. Mathew
Delhi, February 4, 2017
Rural, agriculture and allied sectors get top priority. The allocations are tilted towards schemes and projects that have already been prioritised.


by Joe C. Mathew
Delhi, January 21, 2017
A look at the current years spending by key ministries can help one understand the finance ministers priorities in the Budget


By Joe C. Mathew
Delhi, January 21, 2017
A permanent and independent support system, and a specialised team must guide Parliamentary panels to come up with right solutions.


by Joe C. Mathew
Delhi, December 26, 2016
EM3 provides modern, affordable farm technology services on a pay-per-use basis.


by Joe C. Mathew
Delhi, December 26, 2016
Delhi-based start-up Sabziwala aims to eliminate the middleman, while providing customers with pre-weighed and pre-packed fruit and vegetables.


By Joe C. Mathew
December 1, 2016
For the first time since the Narendra Modi government announced the demonetisation of Rs 500 and Rs 1,000 currency notes, medicine sales have indicated a sharp dip, suggests an analysis of secondary sales trends by market intelligence firm AIOCD AWACS.


BY JOE C. MATHEW AND DIPAK MONDAL WITH Team BT
Delhi, December 4, 2016
The Centre's move to demonetise high-denomination currency has shaken up the economy.


By Joe C. Mathew
Delhi, November 12, 2016
The global agri-biotech major's plans for India are being thwarted by M. Prabhakara Rao, promoter of the country's biggest seed firm Nuziveedu. How the battle plays out will have major ramifications on the seeds industry.


By Anand Adhikari, Joe C. Mathew and Sumant Banerji
Delhi, November 12, 2016
Prime Minister Narendra Modi's shock announcement to demonetise the Rs 500 and Rs 1,000 currency overnight was primarily aimed at catching those who hoard black and illegitimate money in these denominations off-guard. The sudden announcement and its implementation within four hours of the speech may have prevented flight or conversion of such money into other asset classes, but it has also resulted in a lot of collateral damage.


By Joe C. Mathew
Delhi, November 12, 2016
The US President-elect's campaign rhetoric has fathered some queasy questions.


By Joe C Mathew & Rajeev Dubey
Delhi, October 2, 2016
The perception of India outside India has been very positive. Prime Minister Modi has been a key contributor to that increased positive perception. Just from the US perspective, he has been very engaged, very active, says John B. Veihmeyer, Global CEO of KPMG.


By Joe C. Mathew
Delhi, October 5, 2016
One of the earliest diagnoses made by Sun Pharma in the run-up to the Ranbaxy acquisition was that since the entire management was focusing on resolving the US FDA's negative observations, there was a lack of focus towards expanding the business.


PAGES 1 OF 3  123